Healthcare
Viyash Scientific Limited (viyash) Further Strengthens European Companion Animal Presence
Viyash Scientific Limited (VIYASH) acquires Italy’s BioForLife, boosting its European companion animal health market presence.
Viyash Scientific Limited (Viyash), through its wholly owned subsidiary Alivira Animal Health Limited (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of ~₹ 188 crore, is expected to close in Q2 FY27. This strategic move marks a significant step in Viyash’s plan to capitalize on the growing Companion Animal Health Generics market.
Strategic Entry into Europe’s Largest Companion Animal Health Market
The acquisition of BFL is expected to expand Alivira’s global Companion Animal Health business and strengthen its presence in the European pet care market. Italy is among the five largest animal health markets in Europe, with companion animal care emerging as its fastest-growing segment driven by rising pet ownership and spending on veterinary care. BFL specializes in the development, commercialization, and distribution of pet care products, with a strong product portfolio in nutritional complements, pharmaceuticals, and rapid diagnostic tests.
Accelerating Global Pet Care Growth Ambition
The acquisition will provide a platform for launching new products from Alivira’s pipeline in Italy, while simultaneously offering opportunities to expand the BFL range to other markets in the Alivira group located in Europe, Middle East, Asia, and Latam. Dr. Haribabu Bodeputi, Managing Director and Group CEO of Viyash Scientific Limited, emphasized the importance of this acquisition in building a leading global Companion Animal Health business. The combination of BFL’s commercial reach and Alivira’s product development capabilities creates a compelling opportunity to accelerate growth, expand the companion animal portfolio, and deliver greater value to veterinarians, pet owners, and partners across markets.
This transaction also strengthens the Alivira team with the induction of BFL executives who will continue to run the business operations, in addition to driving new growth initiatives. This acquisition further builds on Alivira’s strong track record of global acquisitions, having successfully acquired and integrated animal health companies across Europe, Latam, and Asia in the last 10 years.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Viyash Scientific Limited
Viyash Scientific Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Viyash gains 25.8% over three months and trades near its 52-week highs. Thin margins at 5.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 25.8% in three months on 34.1% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Viyash Scientific Limited.
Healthcare
Sun Pharmaceutical Industries Limited Presents Long-term Data on Unloxcyt® at ESMO 2026
Sun Pharma shares long-term follow-up data on UNLOXCYT® at ESMO 2026, showing 34% CR in locally advanced disease.
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced today that it will present updated long-term efficacy and safety results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) and metastatic CSCC (mCSCC) expansion cohorts from the pivotal CK-301-101 trial of UNLOXCYT® (cosibelimab-ipdl) at the European Society for Medical Oncology (ESMO) Congress on October 24, 2026 in Madrid, Spain.
Key Findings from ESMO 2026 Presentation
The ESMO abstract expands the pivotal analysis to 205 patients across three advanced CSCC cohorts using centrally-reviewed data. Notably, 34% of patients with locally advanced disease achieved a complete response (CR), while 17%-21% of metastatic patients achieved a CR. The tolerability profile remained consistent with earlier analyses, with a low level of high-grade immune-related adverse events (irAEs).
Clinical Implications
These results underscore the potential for cosibelimab to deliver clinically meaningful and durable benefit for patients with advanced CSCC. The consistent benefit-risk profile over time, with maintained response rates and increasing proportion of complete responses, highlights the promising efficacy of UNLOXCYT® in treating advanced skin cancers.
Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma, emphasized, ‘These findings of improvements in clinical response and consistent safety profile of low irAEs over time support the unmet need for patients with advanced CSCC. And reflects Sun Pharma’s continued commitment to advancing care and providing innovative treatment options that address the needs of patients with difficult-to-treat skin cancers.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited Q2fy27 Results Update: Double-digit Growth, Strong Financials
Dr. Reddy’s Laboratories Limited DRREDDY reports double-digit Q2FY27 growth, with ₹8,671 Cr revenue and 20.6% EBITDA margin.
Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.
Financial Highlights
The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.
Strategic Initiatives
Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.
The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
Healthcare
Jupiter Life Line Hospitals Limited (jlhl) Secures Land Acquisition for Pune South Hospital
Jupiter Life Line Hospitals Limited (JLHL) secures land acquisition for Pune South hospital, enhancing growth prospects.
Jupiter Life Line Hospitals Limited (JLHL) has announced the acquisition of land for its Pune South hospital, marking a significant step in its growth strategy. The Board has approved the purchase of 11,452.07 sq. m. of land for Rs 150 cr, with a deposit of Rs 50 cr already paid, resulting in an incremental cash outflow of Rs 100 cr. This strategic move eliminates long-term lease risks and strengthens the company’s asset base in a key growth location.
Q2FY27 Performance Highlights
JLHL’s Q2FY27 performance saw a notable increase in total income to Rs 456.5 cr, up 16% YoY. The EBITDA loss at the new Dombivli hospital was Rs 0.2 cr, significantly lower than the Rs 9.5 cr loss in Q1FY27. The company’s other hospitals performed in line with expectations, contributing to overall growth.
H1FY27 Financial Overview
For H1FY27, JLHL reported total income of Rs 867.5 cr, up 16% compared to H1FY26. The EBITDA margin improved to 22.9%, driven by operational efficiencies and strategic investments. Despite initial ramp-up losses at Dombivli and higher marketing costs, the company remains optimistic about its future growth trajectory.
JLHL continues to focus on expanding its hospital network and enhancing patient care services, positioning itself for sustained growth in the healthcare sector.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Jupiter Life Line Hospitals Limited
Jupiter Life Line Hospitals Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.
Jupiter drops 84.1% over three months and trades near its 52-week lows. The business compounds revenue at 18.9% and profits at 38.6% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. RSI stands at 27, well into oversold territory. Yet sellers still dominated on 23 of recent sessions versus 7 for buyers, so the pressure has not fully lifted. The business compounds at 18.9% revenue and 38.6% profit CAGR, with D/E of 0.00. Yet the stock drops 84.1% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Jupiter Life Line Hospitals Limited.
-
Healthcare2 days agoNureca Limited (nureca) Q2 FY27: Revenue Up 55%, Records Highest Quarterly Revenue in Last 20 Quarters
-
AYE2 days agoAye Finance Limited (NSE: AYE) Q2fy27: Highest-ever Quarterly Profit of INR 87 Crore
-
FSL3 days agoFirstsource Solutions Limited (FSL) Named Horizon 3 Market Leader in HFS Horizons: Customer Experience Services, 2026
-
Basic Materials2 days agoInternational Gemological Institute Limited (igil) Q2 FY27: Certification Revenue Up 32%, Ebitda Growth at 39%
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Partners with Prolific Machines to Scale Biologics Manufacturing
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Receives USFDA Approval for Estradiol and Levonorgestrel
-
INFOBEAN2 days agoInfobeans Technologies Limited (infobean) Achieves Select Partner Tier in the Claude Partner Network Services
-
Information Technology Services2 days agoLtm Limited (LTM) Launches Blueverse™ Valuemesh™ to Help Enterprises Scale AI Across Oracle